Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE: COST | $2.6B Rx revenue 2024 (11th largest US pharmacy); 19%+ prescription growth; below-market drug pricing open to non-members in most states; no PBM markup model
Costco Pharmacy operates as a pharmacy benefit integrated directly into Costco's warehouse membership model, offering prescription drug dispensing at significantly below-market prices by leveraging Costco's bulk purchasing power and low-margin retail philosophy. Founded as an extension of Costco Wholesale's membership warehouse business, the pharmacy operates on the principle that drug costs should be transparent and accessible, a differentiated stance in an industry dominated by opaque PBM pricing arrangements. Costco Pharmacy serves both Costco members and, in most states, non-members who can access the pharmacy counter without a warehouse membership.\n\nThe pharmacy operates across 650+ Costco warehouse locations in the United States, Puerto Rico, and internationally, offering a formulary of generic and brand-name prescription drugs at prices that often undercut major chains by 50–80%. Costco does not participate in most prescription drug insurance networks, which keeps overhead low and pricing simple — members pay a known cash price rather than navigating co-pay structures. The pharmacy also offers compounding services, pet medications, and immunizations at select locations, and integrates with Costco's optical and hearing aid departments to serve the full healthcare needs of its membership base.\n\nCostco Pharmacy is consistently ranked among the lowest-cost pharmacy options in independent drug pricing surveys, creating strong loyalty among members managing chronic conditions or high-cost specialty medications. The pharmacy benefits from Costco's 130 million+ cardholders globally, who view low-cost pharmacy access as one of the core value drivers of their membership. As PBM reform and drug pricing transparency become legislative priorities in the US, Costco's no-frills cash-pay model is increasingly viewed as a reference point for what pharmacy pricing could look like without intermediary markup layers.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.